Venture Beyond
Section 32 is a venture capital firm investing at the frontiers of technology. Founded by Bill Maris, the team has vast experience building iconic companies.
Our goal is to accelerate the discovery, development, and distribution of revolutionary technologies that improve the human condition.
We invest across the entirety of technology. This includes cybersecurity, enterprise software, fintech, web3, quantum computing, space, machine learning, artificial intelligence, computational biology, and biotechnology.
Team
Portfolio
*Exit
- 3EO
- A2
- Alector*
- Arbor Biotech
- Arc Boats
- Aspen Neuroscience
- Auris*
- Autobahn Therapeutics
- Avitide*
- BigHat Biosciences, Inc.
- BloomText
- Brightloom
- C2i Genomics
- Celsius Therapeutics
- Celularity
- Ciitizen*
- Character Bio
- Cohere
- Coinbase*
- CrowdStrike*
- Cue Health*
- Culture Biosciences
- Current Health*
- DA32 Life Science Tech*
- Dave
- Deel
- Dialpad
- Embark
- EQRx*
- Evidation Health
- Exai Bio
- Faro Health
- Fondeadora
- Freenome
- Fulcrum Therapeutics*
- Function Oncology
- Glympse Bio
- Gretel
- Gusto
- ImmuneID
- Inceptive
- Inworld AI
- Kobalt*
- Legacy
- Lime
- Manifold
- Meatable
- MedArrive
- MedCrypt
- Mekonos
- Metaphysic
- Metromile*
- Miroculus
- MOMA Therapeutics
- Neocis
- Nested Therapeutics
- Neuralink
- Nodexus
- NorQuin
- Nucleai
- Nusano
- Octave Bioscience
- ONI
- Parallel
- Parthenon Therapeutics
- Patch Biosciences
- Phaidra
- Pomelo
- Primer
- Raya
- Relay Therapeutics*
- Rome Therapeutics
- Rock
- Sandbox
- Satellite Bio
- ScienceIO
- Sema4*
- Singular Genomics*
- Spectral Finance
- Stairwell
- Swadesh Bank
- Syllable
- Teckro
- Thrive*
- TrialSpark
- TwinStrand
- Venice
- Verge Genomics
- Vir*
- WithMe Health
- Wise Systems
- X4 Pharmaceuticals
- XOKind
- Show all +